Investing in mHealth company founded by Dr. Oz keeps growing

Sharecare, a digital health and wellness engagement platform co-founded by physician and talk show host Mehmet Oz, MD, has closed a $20 million investment from Wellington Management Company.

Trinity Health made a $5 million investment in the company marking a total of $160 million raised by Sharecare since its founding in 2010. This latest growth round of financing will support Sharecare’s expansion plans, including the development and delivery of innovative mobile products and services to help people optimize their health, according to a release.

Trinity initially invested in Sharecare in 2013, through their participation in the Heritage Healthcare Innovation Fund; and in 2014, launched a system-wide partnership with Sharecare to provide Trinity’s communities and patients with a personalized, localized engagement platform.

Since its founding in 2010, Sharecare has raised a total of $160 million in financing, partnering with a diverse group of strategic investors, including media companies like Discovery Communications, Harpo Productions and Hearst Corporation; high-growth technology investment firms such as Claritas Capital; and hospitals and healthcare investment firms, in particular, HCA, Trinity Health and the Heritage Healthcare Innovation Fund.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.